American Society of Interventional Pain Physicians | August 8, 2018
REGISTER NOW!
COMPREHENSIVE REVIEW COURSE
6.75 A MA PRA Category 1 Credits™
AND CADAVER WORKSHOP
11 AMA PRA Category 1 Credits

Neuromodulation Cadaver Workshop will be
limited to 4 physicians per station.
Minimum attendance of 4 physicians required thirty days prior to meeting or
course and workshop is subject to cancellation. Register early!

1 Day Review Course and 1.5 Day Cadaver Workshop.
LIMITED NUMBER OF STATIONS.
NEUROMODULATION WORKSHOP LAB
PROCEDURES INCLUDE:
1. Trial lead placement for low back pain
2. Trial lead placement for neck pain
3. Spinal cord stimulator permanent implant placement (conventional)
4. Wireless trial and permanent placement
5. Transforaminal trial and permanent placement
6. Placement of intrathecal infusion system
7. Intercostal nerve stimulation
8. Sacroiliac stimulation
9. Suprascapular nerve stimulation
10. Free forum

Procedures are subject to change.
|   BROCHURE |   REGISTRATION  |   HOTEL  |   EXHIBITOR |

18 A MA PRA Category 1 Credits™

|   BROCHURE |   REGISTRATION  |   HOTEL  |   EXHIBITOR |

COMPREHENSIVE REVIEW COURSE
6.75 A MA PRA Category 1 Credits™

AND CADAVER WORKSHOP
11 AMA PRA Category 1 Credits
BROCHURE |   REGISTRATION  |   HOTEL  |   EXHIBITOR |

 COMPREHENSIVE REVIEW COURSE
7 AMA PRA Category 1 Credits™
(Plus Free Online Lectures)
AND CADAVER WORKSHOP
11 AMA PRA Category 1 Credits™

How Opioid Drugmakers Tried to Exploit OxyContin Debacle

As Purdue Pharma faced mounting criticism over deaths linked to OxyContin, rival drugmakers saw a chance to boost sales by stepping up marketing of similarly dangerous painkillers, such as fentanyl, morphine, and methadone, Purdue internal documents reveal.
Purdue's 1996-2002 marketing plans for OxyContin, which  Kaiser Health News  made  public  this year for the first time, offer an unprecedented look at how that company spent millions of dollars to push opioids for growing legions of pain sufferers. A wave of lawsuits demanding reimbursement and accountability for the opioid crisis now ravaging communities has heightened awareness about how and when drug makers realized the potential dangers of their products.


GM Cuts Different Type of Health-Care Deal

General Motors  Co.  GM -0.51%  has struck a deal with a Detroit-based hospital system to offer a new coverage option to employees, upending the traditional benefits setup in an attempt to lower costs and improve care.
The auto maker’s agreement with Henry Ford Health System covers everything from doctor visits to surgical procedures. By signing a contract directly with one health-care provider, as other companies have done, GM says it can offer a plan  that costs employees less than other options  while also promising special customer-service perks and quality standards.
GM’s new approach is a departure from  the traditional health-benefits arrangement  in which companies hire insurers for access to a broader network of health-care providers. In those cases, insurers negotiate the prices with hospitals, doctors and other providers, and the employers rarely have access to the terms  that govern their medical costs.



Access to this article may be limited

Medicaid Expansion Under ACA Found to Benefit Access to Treatments for Opioid Use Disorder

States that have adopted  Medicaid expansions under the Affordable Care Act saw an increase in the utilization and availability of treatments for opioid use disorder (OUD), according to a study published in the  Journal of Health Economics .
The study used Medicaid administrative data and Medicaid expansion dates from 2007 to 2016. The researchers measured the effect of Medicaid expansions and Medicaid coverage on OUD treatment utilization, OUD treatment availability, and opioid agonist medication-assisted treatment (MAT) availability.
Aggregate opioid admissions  to specialty treatment facilities were found to have increased by 18% — mainly outpatient MAT — in states that had vs those that had not adopted Medicaid expansion. This trend was driven by a 113% increase in opioid admissions by Medicaid beneficiaries.


Intrathecal Drug Delivery Systems May Be Ineffective for Complex Regional Pain Syndrome

Intrathecal drug delivery  systems may be ineffective in reducing pain and oral opioid intake in individuals with complex regional pain syndrome, according to a study recently published in  Pain Medicine.
This study included 1653 individuals with implanted intrathecal drug delivery systems, 62 of whom had received the device  to alleviate complex regional pain syndrome-related pain (n=26 with ≥ 4 years of follow-up data). Participants in this study received an intrathecal drug delivery system implant between 2000 and 2013. The primary outcomes for this study included pain intensity and oral intake of opioids.


Interventional Pain Management Reports is an Open Access online journal, a peer-reviews journal dedicated to the publication of case reports, brief commentaries and reviews and letters to the editor. It is a peer-reviewed journal written by and directed to an audience of interventional pain physicians, clinicians and basic scientists with an interest in interventional pain management and pain medicine. 

Interventional Pain Management Reports is an official publication of the American Society of Interventional Pain Physicians (ASIPP) and is a sister publication of Pain Physician . Interventional Pain Management Reports Interventional Pain Management Reports is an open access journal, available online with free full manuscripts.  

The benefits of publishing in an open access journal that has a corresponding
print edition journal are:  
  • Your article will have the potential to obtain more citations.
  • Your article will be peer-reviewed and published faster than other journals.
  • Your article can be read by a potentially much larger audience compared with traditional subscription-only journals.  
  • Open Access journals are FREE to view, download and to print.

So submit today your:
  • Case Reports
  • Technical Reports
  • Editorials
  • Short Perspectives

Article Addresses “Most Consequential, Preventable Public Health Problem in the US”

Laxmaiah Manchikanti, MD, Jaya Sanapati, MD, Ramsin M. Benyamin, MD, Sairam Atluri, MD, Alan D. Kaye, MD, PhD, and Joshua A. Hirsch, MD

The opioid epidemic has been called the “most consequential preventable public health problem in the United States.” Though there is wide recognition of the role of prescription opioids in the epidemic, evidence has shown that heroin and synthetic opioids contribute to the majority of opioid overdose deaths.

This manuscript, featured in the July/August issue of Pain Physician, describes the escalation of opioid use in the United States, discussing the roles played by drug manufacturers and distributors, liberalization by the DEA, the Food and Drug Administration (FDA), licensure boards and legislatures, poor science, and misuse of evidence-based medicine.

Data on opioid overdose deaths shows
  • 42,000 deaths in 2016
synthetic opioids other than methadone were responsible for over 20,000
heroin for over 15,000
o natural and semi-synthetic opioids responsible for over 14,000
  • Fentanyl deaths increased 520% from 2009 to 2016
  • Heroin deaths increased 533% from 2000 to 2016
  • Prescription opioid deaths increased by 18% overall between 2009 and 2016.

The Drug Enforcement Administration (DEA) mandated reductions in opioid production by 25% in 2017 and 20% in 2018. The number of prescriptions for opioids declined significantly from 252 million in 2013 to 196 million in 2017.

This manuscript describes a 3-tier approach presented to Congress.
  • Tier 1 includes an aggressive education campaign geared toward the public, physicians, and patients.
  • Tier 2 includes facilitation of easier access to non-opioid techniques and the establishment of a National All Schedules Prescription Electronic Reporting Act (NASPER).
  • Tier 3 focuses on making buprenorphine more available for chronic pain management as well as for medication-assisted treatment.


Pain Physician
July/August 2018 Issue Features

Health Policy Review
  • Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic
Systematic Reviews
  • Is Unilateral Percutaneous Kyphoplasty Superior to Bilateral Percutaneous Kyphoplasty for Osteoporotic Vertebral Compression Fractures? Evidence from a Systematic Review of Discordant Meta-Analyses
  • Prevalence of Recurrent Herniation Following Percutaneous Endoscopic Lumbar Discectomy: A Meta-Analysi
Randomized Trials
  • Thermal Versus Super Voltage Pulsed Radiofrequency of Stellate Ganglion in Post-Mastectomy Neuropathic Pain Syndrome: A Prospective Randomized Trial
  • Evaluation of an Experimental Pain Model by Noncompartmental Analysis of Results from a Randomized Placebo Controlled Trial
  • Transforaminal vs Interlaminar Epidural Steroid Injection for Acute-Phase Shingles: A Randomized, Prospective Trial


DOJ News
Prime Healthcare Services and CEO to Pay $65 Million to Settle False Claims Act Allegations
Prime Healthcare Services, Inc., Prime Healthcare Foundation, Inc., and Prime Healthcare Management, Inc. (collectively Prime), and Prime’s Founder and Chief Executive Officer, Dr. Prem Reddy, have agreed to pay the United States $65 million to settle allegations that 14 Prime hospitals in California knowingly submitted false claims to Medicare by admitting patients who required only less costly, outpatient care and by billing for more expensive patient diagnoses than the patients had (a practice known as “up-coding”), the Justice Department announced today. Under the settlement agreement, Dr. Reddy will pay $3,250,000 and Prime will pay $61,750,000.    
“This settlement reflects our ongoing commitment to ensure that health care providers appropriately bill Medicare,” said Acting Assistant Attorney General Chad A. Readler of the Justice Department’s Civil Division. “Charging the government for higher cost inpatient services that patients do not need, and for higher-paying diagnoses than the patients have, wastes the country’s valuable health care resources.”
Headquartered in Ontario, California, Prime Healthcare Services and not-for-profit Prime Healthcare Foundation constitute one of the largest hospital systems in the nation, with 45 acute-care hospitals located in 14 states. The following 10 hospital defendants owned by Prime Healthcare Services are parties to the settlement agreement: Alvarado Hospital Medical Center, Garden Grove Medical Center, La Palma Intercommunity Hospital, Desert Valley Hospital, Chino Valley Medical Center, Paradise Valley Hospital, San Dimas Community Hospital, Shasta Regional Medical Center, West Anaheim Medical Center and Centinela Hospital Medical Center. The following 4 hospital defendants, owned by Prime Healthcare Foundation, are also parties to the settlement agreement: Sherman Oaks Hospital, Montclair Hospital Medical Center, Huntington Beach Hospital and Encino Hospital Medical Center. Prime Healthcare Management, a subsidiary of Prime Healthcare Services, provides management, consulting and support services to hospitals owned and operated by Prime.

DOJ



Detroit Area Hospital System to Pay $84.5 Million to Settle False Claims Act Allegations Arising From Improper Payments to Referring Physicians
WASHINGTON – William Beaumont Hospital, a regional hospital system based in the Detroit, Michigan area, will pay $84.5 million to resolve allegations under the False Claims Act of improper relationships with eight referring physicians, resulting in the submission of false claims to the Medicare, Medicaid and TRICARE programs, the Justice Department announced today.   
The Anti-Kickback Statute prohibits offering, paying, soliciting, or receiving remuneration to induce referrals of items or services covered by Medicare, Medicaid, and other federally funded programs. The Physician Self-Referral Law, commonly known as the Stark Law, prohibits a hospital from billing Medicare for certain services referred by physicians with whom the hospital has an improper financial arrangement, including the payment of compensation that exceeds the fair market value of the services actually provided by the physician and the provision of free or below-market rent and office staff. Both the Anti-Kickback Statute and the Stark Law are intended to ensure that physicians’ medical judgments are not compromised by improper financial incentives and instead are based on the best interests of their patients.

DOJ
State Society News 

Aug 17-19, 2018
Ohio and Kentucky SIPP Meeting
Click HERE for more information

July 12-14, 2019
GSIPP 2019 - 15th Annual Meeting & Pain Summit
The Cloister Hotel at Sea Island
Sea Island, GA
For more information, contact Karrie Kirwan at karrie@theassociationcompany.com or Tara Morrison at tara@theassociationcompany.com or 770-613-0932.



Send in your state society meeting news to Holly Long, hlong@asipp.org
ASIPP | Pain Physician Journal | Phone | Fax | Email